$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph

$auph Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000162828021009306 Filed on May 06, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$914.0K	$30.00K
YoY Change	2946.67%	0.0%
Cost Of Revenue	$48.00K	$0.00
YoY Change
Gross Profit	$866.0K	$30.00K
YoY Change	2786.67%
Gross Profit Margin	94.75%	100.0%
Selling, General & Admin	$39.28M	$11.05M
YoY Change	255.49%	183.33%
% of Gross Profit	4536.03%	36833.33%
Research & Development	$9.833M	$13.84M
YoY Change	-28.93%	30.15%
% of Gross Profit	1135.45%	46116.67%
Depreciation & Amortization	$688.0K	$0.00
YoY Change		-100.0%
% of Gross Profit	79.45%	0.0%
Operating Expenses	$51.46M	$27.09M
YoY Change	89.95%	81.56%
Operating Profit	-$50.54M	-$27.06M
YoY Change	86.78%	81.72%
Interest Expense	$172.0K	$890.0K
YoY Change	-80.67%	-63.82%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$50.37M	-$26.17M
YoY Change	92.48%	110.71%
Income Tax	$8.000K	-$200.0K
% Of Pretax Income
Net Earnings	-$50.38M	-$25.93M
YoY Change	94.27%	83.95%
Net Earnings / Revenue	-5511.93%	-86440.0%
Basic Earnings Per Share	-$0.40	-$0.23
Diluted Earnings Per Share	-$0.40	-$0.23
COMMON SHARES
Basic Shares Outstanding	127.4M shares
Diluted Shares Outstanding	127.4M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$348.3M	$286.1M
YoY Change	21.73%	98.27%
Cash & Equivalents	$156.6M	$274.2M
Short-Term Investments	$191.7M	$11.90M
Other Short-Term Assets	$1.180M	$8.300M
YoY Change	-85.78%	23.88%
Inventory	$15.94M
Prepaid Expenses	$6.864M
Receivables	$1.187M	$3.500M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$372.2M	$297.9M
YoY Change	24.96%	96.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.758M	$5.900M
YoY Change	-19.36%	1375.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$12.60M
YoY Change
Other Assets	$11.86M	$200.0K
YoY Change	5828.0%	-50.0%
Total Long-Term Assets	$44.83M	$14.80M
YoY Change	202.92%	12.98%
TOTAL ASSETS
Total Short-Term Assets	$372.2M	$297.9M
Total Long-Term Assets	$44.83M	$14.80M
Total Assets	$417.1M	$312.7M
YoY Change	33.38%	90.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.182M	$12.40M
YoY Change	-82.4%	100.0%
Accrued Expenses	$16.59M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$21.15M	$14.50M
YoY Change	45.87%	123.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$17.90M	$19.10M
YoY Change	-6.28%	4.37%
Total Long-Term Liabilities	$17.90M	$19.10M
YoY Change	-6.28%	2.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.15M	$14.50M
Total Long-Term Liabilities	$17.90M	$19.10M
Total Liabilities	$46.85M	$33.70M
YoY Change	39.02%	33.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$625.5M
YoY Change
Common Stock	$43.89M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$370.2M	$279.1M
YoY Change
Total Liabilities & Shareholders Equity	$417.1M	$312.7M
YoY Change	33.38%	90.09%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$50.38M	-$25.93M
YoY Change	94.27%	83.95%
Depreciation, Depletion And Amortization	$688.0K	$0.00
YoY Change		-100.0%
Cash From Operating Activities	-$53.54M	-$22.61M
YoY Change	136.82%	71.92%
INVESTING ACTIVITIES
Capital Expenditures	-$1.181M	$210.0K
YoY Change	-662.38%	950.0%
Acquisitions
YoY Change
Other Investing Activities	-$66.07M	-$11.91M
YoY Change	454.71%	-404.6%
Cash From Investing Activities	-$67.25M	-$12.13M
YoY Change	454.57%	-411.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$5.029M	$2.922M
YoY Change	72.11%	-90.77%
NET CHANGE
Cash From Operating Activities	-$53.54M	-$22.61M
Cash From Investing Activities	-$67.25M	-$12.13M
Cash From Financing Activities	$5.029M	$2.922M
Net Change In Cash	-$115.8M	-$31.81M
YoY Change	263.88%	-242.08%
FREE CASH FLOW
Cash From Operating Activities	-$53.54M	-$22.61M
Capital Expenditures	-$1.181M	$210.0K
Free Cash Flow	-$52.36M	-$22.82M
YoY Change	129.47%	73.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	BC
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001600620
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-36421
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	Aurinia Pharmaceuticals Inc.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	Z4
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	#1203-4464 Markham Street
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Victoria
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V8Z 7X8
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-4129078
CY2021Q1	dei	City Area Code CityAreaCode	(250)
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	708-4272
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	128156427	shares
CY2021Q1	dei	Security12b Title Security12bTitle	Common shares, no par value
CY2021Q1	dei	Trading Symbol TradingSymbol	AUPH
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	156591000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	272350000	USD
CY2021Q1	us-gaap	Debt Securities Current DebtSecuritiesCurrent	191668000	USD
CY2020Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	125979000	USD
CY2021Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1187000	USD
CY2020Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	0	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	15936000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	13927000	USD
CY2021Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6864000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7171000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	372246000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	419427000	USD
CY2021Q1	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	12603000	USD
CY2020Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	24380000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11856000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	247000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4758000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4786000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9854000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9332000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5761000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5489000	USD
CY2021Q1	us-gaap	Assets Assets	417078000	USD
CY2020Q4	us-gaap	Assets Assets	463661000	USD
CY2021Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	17694000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24797000	USD
CY2021Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	2000000	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	6000000	USD
CY2021Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2382000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6412000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1075000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	788000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	21151000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31997000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	17893000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16295000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7806000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7619000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	46850000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	55911000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	128121000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	128121000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	126725000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	126725000	shares
CY2021Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	952673000	USD
CY2020Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	944328000	USD
CY2021Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	43889000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	39383000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-799000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-805000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-625535000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-575156000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	370228000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	407750000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	417078000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	463661000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	914000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30000	USD
CY2021Q1	us-gaap	Cost Of Revenue CostOfRevenue	48000	USD
CY2020Q1	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39282000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11053000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9833000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13835000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	523000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	286000	USD
CY2021Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1771000	USD
CY2020Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1916000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	51457000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	27090000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-50543000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-27060000	USD
CY2021Q1	us-gaap	Interest Income Other InterestIncomeOther	172000	USD
CY2020Q1	us-gaap	Interest Income Other InterestIncomeOther	890000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-50371000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26170000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-238000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-50379000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	USD
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	6000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-50373000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25932000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	127401000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112209000	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	407750000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4999000	USD
CY2021Q1	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	31000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7821000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-50379000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	370228000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	298600000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2920000	USD
CY2020Q1	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	2000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3496000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-25932000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	279086000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-50379000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	165000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	12000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	523000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	286000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7821000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3496000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2111000	USD
CY2020Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-870000	USD
CY2021Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1187000	USD
CY2020Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	0	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2009000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-308000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2661000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-229000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2021Q1	auph	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	272000	USD
CY2020Q1	auph	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	5764000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7103000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1234000	USD
CY2021Q1	auph	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	474000	USD
CY2020Q1	auph	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	5851000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53541000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22608000	USD
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	115168000	USD
CY2020Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	11913000	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	60940000	USD
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2021Q1	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	136000	USD
CY2020Q1	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	79000	USD
CY2021Q1	us-gaap	Payments To Acquire Lease Receivables PaymentsToAcquireLeaseReceivables	11838000	USD
CY2020Q1	us-gaap	Payments To Acquire Lease Receivables PaymentsToAcquireLeaseReceivables	0	USD
CY2021Q1	us-gaap	Payments For Software PaymentsForSoftware	1039000	USD
CY2020Q1	us-gaap	Payments For Software PaymentsForSoftware	86000	USD
CY2021Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	6000	USD
CY2020Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	48000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-67247000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12126000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4999000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2920000	USD
CY2021Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	30000	USD
CY2020Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5029000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2922000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-115759000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-31812000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	272350000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	306019000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	156591000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	274207000	USD
CY2021Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	425000	USD
CY2020Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	891000	USD
CY2021Q1	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements for the three months ended March 31, 2021 have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December 31, 2020 was derived from audited annual financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the full year or any other future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one operating segment in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company operates in one operating segment engaged in the research, development and commercialization of therapeutic drugs in which revenues are derived from license, contract and product revenues. The Company's chief operating decision maker (CODM), the chief executive officer, makes decisions based on the Company as a whole. Accordingly, the Company operates and makes decisions as one reporting unit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements are presented in U.S. dollars which is the Company's functional currency therefore there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statement of operations. All assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are translated at the average exchange rate during the period. Equity transactions are translated using historical exchange rates. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the condensed consolidated statements of operations.</span></div>We are devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. Taking into consideration the Company's cash and cash equivalents of $156.6 million and short term investments of $191.7 million as of March 31, 2021, the Company believes that it has sufficient resources to fund its operations at least one year beyond the date that the unaudited condensed consolidated financial statements are issued.
CY2021Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021Q1	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reportingUnit
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	156600000	USD
CY2021Q1	us-gaap	Debt Securities Current DebtSecuritiesCurrent	191700000	USD
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP, requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We believe the most complex judgments result primarily from the need to make estimates about the effects of matters that are inherently uncertain and are significant to our condensed consolidated financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We evaluate our estimates, judgments and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions and such differences may be material.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant areas involving estimates, judgments and assumptions used in the preparation of our condensed consolidated financial statements are as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue recognition;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost of sales;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inventory;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty obligation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contingent accruals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trial liabilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Share-based compensation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible assets; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Income taxes.</span></div>
CY2021Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, investments and accounts receivable. The Company attempts to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. The Company established guidelines related to credit ratings and maturities intended to safeguard principal balances, earn a return on investments and to maintain liquidity. The Company's investment portfolio is maintained in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company may at times maintain cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk. The Company is exposed to financial risk related to the fluctuation of foreign currency exchange rates which could have a material effect on its future operating results or cash flows. Foreign currency risk is the risk that variations in exchange rates between the United States dollar and foreign currencies, primarily with the Canadian dollar, will affect the Company's operating and financial results. The Company holds the majority of its cash and cash equivalents in U.S. dollars and the majority of its expenses are also denominated in U.S. dollars, which limits the risk of material foreign exchange fluctuations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has three main customers for U.S. commercial sales of LUPKYNIS and one customer for sales of voclosporin in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Revenues from two specialty pharmacies accounted for approximately 59% and 37% of the Company's total revenues. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the </span></div>status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. An allowance against accounts receivable is established, if needed, using an expected credit loss model. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and the Company could potentially incur credit losses.
CY2020Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	150400000	USD
CY2021Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1200000	USD
CY2021Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2021Q1	us-gaap	Debt Securities Current DebtSecuritiesCurrent	191700000	USD
CY2021Q1	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	12600000	USD
CY2020Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	126000000.0	USD
CY2020Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	24400000	USD
CY2021Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	89100000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	115200000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
CY2021Q1	us-gaap	Debt Securities Current DebtSecuritiesCurrent	191668000	USD
CY2020Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	125979000	USD
CY2021Q1	auph	Debt Securities Current And Noncurrent DebtSecuritiesCurrentAndNoncurrent	204271000	USD
CY2020Q4	auph	Debt Securities Current And Noncurrent DebtSecuritiesCurrentAndNoncurrent	150359000	USD
CY2021Q1	us-gaap	Interest Receivable InterestReceivable	400000	USD
CY2020Q4	us-gaap	Interest Receivable InterestReceivable	500000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	6000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	200000	USD
CY2021Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	14367000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	13927000	USD
CY2021Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1569000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	15936000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	13927000	USD
CY2021Q1	us-gaap	Prepaid Advertising PrepaidAdvertising	4139000	USD
CY2020Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	3701000	USD
CY2021Q1	us-gaap	Prepaid Insurance PrepaidInsurance	939000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2054000	USD
CY2021Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1180000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1018000	USD
CY2021Q1	auph	Prepaid Rent And Prepaid Continuing Studies PrepaidRentAndPrepaidContinuingStudies	606000	USD
CY2020Q4	auph	Prepaid Rent And Prepaid Continuing Studies PrepaidRentAndPrepaidContinuingStudies	398000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6864000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7171000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P11Y
CY2021Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19496000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9642000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9854000	USD
CY2020	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P11Y
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	18452000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9120000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9332000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5104000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4965000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	346000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	179000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4758000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4786000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	0	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5761000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5489000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1075000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	788000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7806000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7619000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	8881000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8407000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	261000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	65000	USD
CY2021Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	7000	USD
CY2020Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	76000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	41000	USD
CY2020Q1	us-gaap	Variable Lease Cost VariableLeaseCost	1000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	309000	USD
CY2020Q1	us-gaap	Lease Cost LeaseCost	142000	USD
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y18D
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0518
CY2021Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2182000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	484000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1144000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1061000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1085000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1110000	USD
CY2021Q1	auph	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	6773000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11657000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2776000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	8881000	USD
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	11800000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	91000000.0	USD
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2635000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9727000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10855000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5785000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11307000	USD
CY2021Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	17694000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24797000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	17900000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16300000	USD
CY2021Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	204271000	USD
CY2021Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	360862000	USD
CY2020Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	150359000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	422709000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-50379000	USD
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	127401000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112209000	shares
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15785000	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11375000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	128100000	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	128100000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	126700000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0.000	USD
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	126700000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	16000000.0	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	15800000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.66
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.43
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0028
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0120
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
CY2021Q1	auph	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.089
CY2020Q1	auph	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.130
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0.000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.72
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.44
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7821000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3496000	USD
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	36600000	USD
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y3M18D
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-200000	USD
CY2021Q1	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	25400000	USD

Files In Submission

Name	View Source	Status
0001628280-21-009306-index-headers.html	Edgar Link	pending
0001628280-21-009306-index.html	Edgar Link	pending
0001628280-21-009306.txt	Edgar Link	pending
0001628280-21-009306-xbrl.zip	Edgar Link	pending
auph-20210331.htm	Edgar Link	pending
auph-20210331.xsd	Edgar Link	pending
auph-20210331xexx311.htm	Edgar Link	pending
auph-20210331xexx312.htm	Edgar Link	pending
auph-20210331xexx321.htm	Edgar Link	pending
auph-20210331xexx322.htm	Edgar Link	pending
auph-20210331_cal.xml	Edgar Link	unprocessable
auph-20210331_def.xml	Edgar Link	unprocessable
auph-20210331_htm.xml	Edgar Link	completed
auph-20210331_lab.xml	Edgar Link	unprocessable
auph-20210331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph

2021 Q1 Form 10-Q Financial Statement

#000162828021009306 Filed on May 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUPH Aurinia Pharmaceuticals Inc. Stock $auph

2021 Q1 Form 10-Q Financial Statement

#000162828021009306 Filed on May 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph